You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.
Christopher Simon was appointed CEO on May 16, 2016. Previously, he served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. He brings over 20 years of experience helping businesses transform and grow.
Mr. Simon was the lead partner for the strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the business and our markets. Together with management and the board of directors, he co-architected the strategic plan that we are now implementing.
He was with McKinsey since 1993. Prior to that he served in commercial and operating roles at Baxter Healthcare Corporation, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion.
Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.
Bill Burke joined Haemonetics as Chief Financial Officer in August of 2016 and is responsible for the global finance organization including investor relations. Previously, Mr. Burke was Chief Integration Officer and Vice President, Integration for the Medtronic/Covidien merger. Prior to this role, Mr. Burke worked at Covidien for over nine years in various finance leadership roles including Chief Financial Officer for Europe, Vice President of Corporate Strategy and Portfolio Management and Vice President of FP&A.
Prior to Covidien, he held a number of roles within FP&A and Corporate Audit at Tyco Healthcare Group. Mr. Burke holds a Bachelor of Science in Business Administration from Bryant College with a focus in Accounting and is a Certified Public Accountant (CPA.)
KEVIN F. O'KELLY-LYNCH
Kevin O’Kelly-Lynch joined Haemonetics in December 2016 as Senior Vice President, Global Business Services. He has an extensive and seasoned background in global business and shared services spanning customer service and tech support, finance, procurement, IT, fleet and sales operations. He brings to Haemonetics the knowledge and experience to help us successfully transform the way we create enabling platforms to deliver critical services across multiple functions.
Mr. O’Kelly-Lynch most recently served as Vice President, Medtronic Business Services, where he led the Global Business Services Integration activity post the acquisition of Covidien, and managed a service delivery team of over 600 deployed in the United States, Europe and India. Prior to Medtronic, he was Vice President, Assistant Treasurer at Covidien plc, where he was responsible for global treasury operations. He has also held the position of International Treasurer & Managing Director at Tyco International, and Transfer Pricing Manager and Management Accountant at Diageo plc. He began his career at Fujitsu.
Mr. O’Kelly-Lynch received a Bachelor of Science in Management from Trinity College, Dublin and is a Chartered Global Management Accountant (CGMA).
Ian Purdy, PhD, joined Haemonetics in March 2017 as Senior Vice President, Global Quality and Regulatory Affairs. He is responsible for Haemonetics' global quality programs and regulatory product approvals and agency relationships.
Dr. Purdy has over 20 years of experience in medical devices and diagnostics spanning all regions of the world, along with extensive experience in new product submissions, most especially in China, Europe, Japan and the US.
Most recently, he was Vice President, Clinical Regulatory and Quality Compliance at Thermo Fisher Scientific since 2012. He was responsible for the oversight and coordination of worldwide regulatory and quality compliance, overseeing a team of 2,500 employees at more than 100 global sites. He also held numerous clinical, regulatory and quality roles of increasing scope at Boston Scientific between 2000 and 2012, playing a critical role in ensuring regulatory and quality excellence for innovation-based products. He began his career working in clinical research at Smiths Medical.
Dr. Purdy holds a PhD in Human Physiology (Haemodynamics) from the University of Southampton in the UK, an expertise that is highly relevant to many of our products and programs.
Neil Ryding joined Haemonetics in 2015 as Executive Vice President, Global Operations. Prior to joining Haemonetics, Mr. Ryding had over 30 years of experience in leading global manufacturing operations and supply chain organizations in regulated environments within the aerospace and medical devices. His various roles have taken him around the world with complex and global companies including Rolls Royce Aero-Engines, Johnson & Johnson, Smith & Nephew, Cardinal Health and Hospira, with each role requiring a broad breadth of operational knowledge and complexity.
Carter Houghton joined Haemonetics in December 2016 as President, Hospital Business Unit. He is a highly accomplished leader with a deep knowledge of the hospital segment and a track record of turning around and growing healthcare businesses.
Mr. Houghton’s experience spans division leadership, product marketing and business development roles at Hologic, Inc., where most recently he served as Senior Vice President and General Manager, GYN Surgical Solutions. Prior to Hologic he held various roles of increasing responsibility at Verrillon and Corning, Inc. During his time at Corning, Mr. Houghton spent five years in the Company’s Clinical Labs Division which was later spun off into Quest Diagnostics.
Mr. Houghton holds an MBA from the University of Virginia's Darden School of Business, and a Bachelor of Arts in Journalism and History from the University of Richmond. He also completed an executive education program in Negotiation from the Said Business School at Oxford University.
Patrick Loh joined Haemonetics in 2014 as President of Asia Pacific and is responsible for the region’s oversight of all of Haemonetics’ commercial operations.
Prior to joining Haemonetics, Mr. Loh spent 12 years at Thermo Fisher Scientific as Vice President and General Manager of the Asia Pacific Region with Laboratory Products Group and subsequently at Research and Safety Group. He was instrumental in expanding the business growth and commercial presence throughout the region and also successfully integrated numerous acquired companies throughout his tenure.
Earlier in his career, Mr. Loh held an executive leadership position at Kinetic Concepts Inc. as President Asia Pacific and Executive Committee Member. He started his career at B. Braun Medical AG and progressed through multiple leadership positions of sales, marketing and general management.
Mr. Loh holds an Executive MBA from Olin Business School, Washington University, St Louis and has completed advanced strategic and leadership programs from INSEAD and Babson College.
Thomas McCurdy joined Haemonetics in 2010 as Vice President, North American Patient Sales. Mr. McCurdy championed the development of the company’s innovative Comprehensive Blood Management Solutions (CBMS) initiative. He also led the growth and development of the TEG business in North America, and drove the integration of software and device “connectivity” as a critical platform for customer and market engagement. He was promoted to President, Global Plasma in 2015. Prior to joining Haemonetics, Mr. McCurdy gained 25 years of worldwide sales experience in roles of increasing responsibility at Navilyst Medical, Boston Scientific and Procter & Gamble.
Byron Selman joined Haemonetics in 2012 as President, North America. In January of 2015, Mr. Selman was promoted to President, Americas with the integration of our Latin American business into North America. Mr. Selman was then promoted to President, Global Markets in April 2015. Mr. Selman was previously with Pall Corporation for 21 years where he most recently served as President of Global Medical since 2010.
He began his career in Engineering and took on positions of progressive responsibility in Product Development, Product Management, Global Marketing, and Sales Management before assuming responsibility of a multi-disciplinary group chartered with the development and commercialization of a new line of diagnostic blood products. He later became VP of Global Blood Product Management in 2002, and Senior VP of the Transfusion Medicine Business in 2007. Mr. Selman played an important role with Pall in the sale of the blood business to Haemonetics. He holds a BS in Mechanical Engineering from Case Western Reserve University and an MBA in Finance from Hofstra University.
Wayne Yasutomi joined Haemonetics in December 2013 as President, Japan and is responsible for the region’s commercial operations. Mr. Yasutomi has over 26 years of experience in medical devices in both Japan and the United States. He began his career with Advanced Cardiovascular Systems (Guidant) in marketing, and then joined Boston Scientific Japan where he held various leadership positions in sales, marketing, strategy, and business development.
Prior to joining Haemonetics, Mr. Yasutomi was the head of Japan for Kinetics Concepts International, Biomet 3i, and Biotronik. Mr. Yasutomi holds a Bachelor and Master of Arts from the University of Hawaii, and an MBA from the University of California, Berkeley’s Haas School of Business.
Jan Hartmann, M.D. joined Haemonetics as Vice President, Head of Strategic Programs in August of 2016 with responsibility for the Project Management Office (PMO) and execution of corporate strategic priorities. Previously, Dr. Hartmann was an Associate Partner in the global pharmaceuticals and medical devices practice at McKinsey & Company. He held roles of increasing depth and breadth throughout his career at McKinsey which included being the founder and leader of the respiratory and hemophilia disease area expert teams, as well as leading the global Medical Affairs team.
Prior to joining McKinsey, Dr. Hartmann was a Urology Resident at the University Hospital in Muenster Germany. He holds his M.D. from Albert Ludwigs University of Freiburg in Germany and his medical licensing and board certification from the Ludwig Maxmillians University of Munich also in Germany. Additionally, Dr. Hartmann was a research scholar in the Department of Cell Biology at Yale University School of Medicine.
© 2011-2017 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184